The development of drug resistance limits the survival or patients with small cell anaplastic carcinoma of the lung (SCLC). The present study was undertaken to overcome this problem by administering two alternating noncross resistant combination chemotherapy regimens. One-hundred-one patients were e
Extensive disease small cell carcinoma of the lung. Trial of non-cross resistant chemotherapy and consolidation radiotherapy
โ Scribed by Robert O. Dillman; Raymond Taetle; Stephen Seagren; Ivor Royston; James Koziol; John Mendelsohn
- Publisher
- John Wiley and Sons
- Year
- 1982
- Tongue
- English
- Weight
- 547 KB
- Volume
- 49
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Twenty previously untreated patients with small cell carcinoma of the lung were treated with cyclophosphamide, 400 mg/m2 and Adriamycin, 40 mg/m2 IV on day 1, followed by cytosine arabinoside, 20 mg/m2, every 12 hours subcutaneously on days 5--9; this regimen was repeated every 28 days. On days 14--
In a randomized study 145 patients with extensive small cell carcinoma of the lung were treated with chemotherapy alone (Cytoxan, CCNU, methotrexate) or with the same drug regimen and with radiation therapy to the brain, chest, and abdomen. One hundred eighteen of these patients were evaluable. Thos